C4 Therapeutics CCCC
NASDAQ CCCC
$3.74 +0.00 (+0.13%)
As of: Sep 4, 2026 · 2:36 PM EDT

C4 Therapeutics (CCCC) Operating Income Growth (3y) (2022 - 2026)

Analysis

C4 Therapeutics (CCCC) Operating Income Growth (3y) (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.77 Bn 130.92 Bn 2.84 Bn 6.70%
2 Regeneron Pharmaceuticals 85.51 Bn 77.52 Bn 3.93 Bn 8.36%
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn 89.72%
4 Moderna 58.20 Bn 53.06 Bn 52.00 Mn 24.14%
5 Revolution Medicines 44.04 Bn 44.04 Bn - -
6 BeOne Medicines 39.99 Bn 34.89 Bn 1.53 Bn 44.54%
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn 44.34%
8 Royalty Pharma 28.40 Bn 27.56 Bn - -18.82%
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn 81.27%
10 C4 Therapeutics 492.07 Mn 238.41 Mn - 11.07%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 11.07%
Mar 31, 2026 8.46%
Dec 31, 2025 15.45%
Sep 30, 2025 -1.94%
Jun 30, 2025 -1.34%
Mar 31, 2025 2.40%
Dec 31, 2024 -35.21%
Sep 30, 2024 -5.21%
Jun 30, 2024 1.03%
Mar 31, 2024 -16.25%
Dec 31, 2023 -25.57%
Sep 30, 2023 -14.86%
Jun 30, 2023 -51.24%
Mar 31, 2023 -43.20%
Dec 31, 2022 -53.93%
Sep 30, 2022 -48.10%